Rivanicline oxalate is an investigational research compound primarily studied for the treatment of nicotine addiction and smoking cessation. It acts as a partial agonist at nicotinic acetylcholine receptors, particularly the α4β2 subtype, which helps reduce cravings and withdrawal symptoms in preclinical and clinical studies. The oxalate salt form enhances stability, solubility, and bioavailability, making it suitable for research applications in controlled dosages. It has been explored as part of comprehensive smoking cessation programs, including behavioral therapy, and may offer benefits for individuals who have not succeeded with other methods. Currently, it is not approved for clinical use and is mainly utilized in pharmacological research on nicotine dependence mechanisms and novel cessation therapies.